Vicagrel API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Vicagrel | CAS No: 1314081-53-2 | GMP-certified suppliers
A medication that acts as an investigational antiplatelet agent for managing thrombotic and cardiovascular diseases by modulating platelet aggregation and supporting clinical trial development.
Therapeutic categories
Product Snapshot
- Vicagrel is an oral small molecule antiplatelet agent
- It is primarily developed for the prevention of thrombotic cardiovascular events
- The product is currently in the investigational stage and not yet approved by major regulatory agencies
Clinical Overview
Pharmacologically, Vicagrel is identified as a substrate of cytochrome P450 enzymes, notably CYP2C19, indicating metabolism via hepatic oxidative pathways common to many antiplatelet drugs. The involvement of CYP2C19 may influence interindividual variability in drug response and potential drug-drug interactions. However, detailed pharmacodynamics, precise mechanism of action, and comprehensive ADME profiles remain to be fully elucidated in published literature.
Safety and toxicity data are currently limited as Vicagrel remains in investigational stages; ongoing clinical trials aim to characterize its adverse event profile and tolerability across patient populations. Given its classification and metabolic pathway, consideration of CYP2C19 polymorphisms and potential bleeding risks may be relevant in future clinical evaluations.
Vicagrel is not yet approved for clinical use and lacks marketed brand names globally. Its development appears focused on cardiovascular and thrombotic indications, aligned with the therapeutic niche of antiplatelet agents.
From an API sourcing perspective, stringent quality control is essential due to its investigational status and metabolic complexity. Suppliers must ensure batch-to-batch consistency, purity, and compliance with Good Manufacturing Practice (GMP) standards. Analytical methods capable of detecting impurities and confirming the compound’s identity should be validated to support regulatory submissions and clinical trial requirements.
Identification & chemistry
| Generic name | Vicagrel |
|---|---|
| Molecule type | Small molecule |
| CAS | 1314081-53-2 |
| UNII | 8A63K3TN0U |
| DrugBank ID | DB16349 |
Pharmacology
Targets
| Target | Organism | Actions |
|---|---|---|
| P2Y purinoceptor 12 | Humans | antagonist, inhibitor |
Formulation & handling
- Vicagrel is a small molecule with low aqueous solubility, requiring formulation strategies to enhance dissolution for oral administration. Its moderate lipophilicity (LogP 3.81) suggests potential for permeability-driven absorption but may present formulation challenges. Stability and handling considerations should account for its investigational status and limited solubility profile.
Regulatory status
Vicagrel is a type of Platelet Aggregation Inhibitors
Platelet Aggregation Inhibitors are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) used in the field of cardiology and thrombosis management. These inhibitors play a vital role in preventing platelet aggregation, a process responsible for the formation of blood clots. By inhibiting platelet aggregation, these APIs reduce the risk of arterial thrombosis, which can lead to severe cardiovascular events like heart attacks and strokes.
Platelet Aggregation Inhibitors primarily work by targeting specific receptors on platelet cells, thereby impeding their activation and subsequent aggregation. The most commonly utilized APIs in this category include acetylsalicylic acid (aspirin), clopidogrel, ticagrelor, and prasugrel. These drugs are available in various forms, such as tablets, capsules, and intravenous formulations, allowing flexibility in their administration.
The effectiveness of Platelet Aggregation Inhibitors lies in their ability to prevent platelets from adhering to each other and forming clots within blood vessels. This property is especially crucial in patients with a high risk of cardiovascular events, such as those with a history of heart disease, diabetes, or peripheral artery disease.
While Platelet Aggregation Inhibitors are generally safe and effective, they can also carry potential side effects, including bleeding complications. Therefore, their administration requires careful consideration of individual patient characteristics and risk factors.
In conclusion, Platelet Aggregation Inhibitors represent a significant category of pharmaceutical APIs used for the prevention of platelet aggregation and subsequent blood clot formation. By inhibiting this process, they contribute to the management and reduction of cardiovascular events, offering critical benefits to patients at risk.
